Maxim Group Issues a Buy Rating on GW Pharma


Maxim Group Issues a Buy Rating on GW Pharma

By Ryan Adsit

Maxim Group analyst Lauren Chung reiterated a Buy rating on GW Pharma (NASDAQ: GWPH) today and set a price target of $135. The company’s shares opened today at $115.82.

Chung said:

“Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of $5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS).”

According to TipRanks.com, Chung is a 2-star analyst with an average return of 2.0% and a 77.8% success rate. Chung covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals,

... read more at: http://www.analystratings.com/2017/04/20/maxim-group-issues-a-buy-rating-on-gw-pharma/

by